



(43) International Publication Date
4 April 2013 (04.04.2013)

(51) International Patent Classification:
C07D 413/04 (2006.01) *A61P 35/00* (2006.01)
A61K 31/497 (2006.01)

(21) International Application Number: PCT/US2012/058127

(22) **International Filing Date:** 28 September 2012 (28.09.2012)

(25) **Filing Language:** English

(26) **Publication Language:** English

(30) Priority Data:
61/541,865 30 September 2011 (30.09.2011) US

(71) **Applicant** (for all designated States except US): **VERTEX PHARMACEUTICALS INCORPORATED** [US/US]; 130 Waverly Street, Cambridge, MA 02139 (US).

(72) **Inventors; and**

(71) **Applicants (for US only):** **CHARRIER, Jean-damien** [FR/GB]; Unit 88, Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). **STUDLEY, John** [GB/GB]; Unit 88, Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). **PIERARD, Francoise Yvonne Theodora Marie** [BE/GB]; Unit 88, Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). **DURRANT, Steven John** [GB/GB]; Unit 88, Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). **LITTLER, Benjamin Joseph** [GB/US]; 7016 Ivy Street, Carlsbad, CA 92011 (US). **HUGHES, Robert Michael** [GB/US]; 10235 Arrow Rock Avenue, San Diego, CA 92126 (US). **SIESEL, David Andrew** [US/US]; 11145 Papoose Court, San Diego, CA 92127 (US). **ANGELL, Paul. URBINA, Armando** [US/US]; 4755 Castle Island Cove, San Diego, CA 92154 (US). **SHI, Yi** [US/US]; 80 Rathbun Road, Natick, MA 01760 (US).

(74) **Agent: CHE, Jennifer G.;** Vertex Pharmaceuticals Incorporated, 130 Waverly Street, Cambridge, Massachusetts 02139 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:


- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) **Date of publication of the international search report:**
6 June 2013

(54) Title: PROCESSES FOR MAKING COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE



(I)



(II)

(57) Abstract: The present invention relates to processes and intermediates for preparing compounds useful as inhibitors of ATR kinase, such as aminopyrazine-isoxazole derivatives and related molecules. The present invention also relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula (I) or (II) wherein the variables are as defined herein.